Acquisitions and Divestitures - Purchase Price Allocation (Details) - USD ($) $ in Millions			12 Months Ended
	Mar. 01, 2016	Jan. 22, 2016	Dec. 31, 2016	Apr. 01, 2017
Assets acquired:
Goodwill			$ 4,049.4	$ 4,076.1
Tretinoin
Business Acquisition [Line Items]
Purchase price paid		$ 416.4
Contingent consideration		0.0
Total purchase consideration		416.4
Assets acquired:
Cash and cash equivalents		0.0
Accounts receivable		0.0
Inventories		1.4
Prepaid expenses and other current assets		0.0
Property and equipment		0.0
Goodwill		1.7
Total intangible assets		413.3
Total assets		416.4
Liabilities assumed:
Accounts payable		0.0
Accrued liabilities		0.0
Long-term debt		0.0
Net deferred income tax liabilities		0.0
Total liabilities		0.0
Net assets acquired		416.4
Tretinoin | In-process research and development
Assets acquired:
In-process research and development		0.0
Tretinoin | Licensing Agreements
Assets acquired:
Definite-lived intangibles:		0.0
Tretinoin | Developed technology rights
Assets acquired:
Definite-lived intangibles:		411.0
Tretinoin | Customer Relationships
Assets acquired:
Definite-lived intangibles:		0.0
Tretinoin | Non-compete agreements
Assets acquired:
Definite-lived intangibles:		$ 2.3
Development stage rx products
Business Acquisition [Line Items]
Purchase price paid	$ 0.0
Contingent consideration	24.9
Total purchase consideration	24.9
Assets acquired:
Cash and cash equivalents	0.0
Accounts receivable	0.0
Inventories	0.0
Prepaid expenses and other current assets	0.0
Property and equipment	0.0
Goodwill	0.0
Total intangible assets	24.9
Total assets	24.9
Liabilities assumed:
Accounts payable	0.0
Accrued liabilities	0.0
Long-term debt	0.0
Net deferred income tax liabilities	0.0
Total liabilities	0.0
Net assets acquired	24.9
Development stage rx products | In-process research and development
Assets acquired:
In-process research and development	24.9
Development stage rx products | Licensing Agreements
Assets acquired:
Definite-lived intangibles:	0.0
Development stage rx products | Developed technology rights
Assets acquired:
Definite-lived intangibles:	0.0
Development stage rx products | Customer Relationships
Assets acquired:
Definite-lived intangibles:	0.0
Development stage rx products | Non-compete agreements
Assets acquired:
Definite-lived intangibles:	$ 0.0
All Other
Business Acquisition [Line Items]
Purchase price paid			17.1
Contingent consideration			26.2
Total purchase consideration			43.3
Assets acquired:
Cash and cash equivalents			3.8
Accounts receivable			4.9
Inventories			7.1
Prepaid expenses and other current assets			0.1
Property and equipment			1.2
Goodwill			0.0
Total intangible assets			32.9
Total assets			50.0
Liabilities assumed:
Accounts payable			2.8
Accrued liabilities			0.1
Long-term debt			3.3
Net deferred income tax liabilities			0.5
Total liabilities			6.7
Net assets acquired			43.3
All Other | In-process research and development
Assets acquired:
In-process research and development			4.9
All Other | Licensing Agreements
Assets acquired:
Definite-lived intangibles:			1.8
All Other | Developed technology rights
Assets acquired:
Definite-lived intangibles:			18.0
All Other | Customer Relationships
Assets acquired:
Definite-lived intangibles:			8.2
All Other | Non-compete agreements
Assets acquired:
Definite-lived intangibles:			$ 0.0